Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion

DRUG4 trials

Sponsors

Iovance Biotherapeutics Inc., Institut Paoli Calmettes, Universitair Ziekenhuis Gent

Conditions

MelanomaMetastatic Non-Small-Cell Lung CancerPatients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapyacute myeloid lymphomafor hematological malignancy

Phase 2

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

RecruitingCTIS2024-510778-26-00

Iovance Biotherapeutics Inc.Metastatic Non-Small-Cell Lung Cancer

Start: 2025-12-19Target: 115Updated: 2025-11-26

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

Not yet recruitingCTIS2025-523632-39-00

Institut Paoli Calmettesacute myeloid lymphoma

Target: 77Updated: 2026-08-17

Phase 3

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma

RecruitingCTIS2022-503140-41-00

Iovance Biotherapeutics Inc.Melanoma

Start: 2024-11-29Target: 280Updated: 2025-10-31

Phase 4

Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy

Not yet recruitingCTIS2025-524278-40-00

Universitair Ziekenhuis GentPatients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy, for hematological malignancy

Target: 75Updated: 2026-03-23